Ornithine Transcarbamylase Deficiency via the OTC Gene
Use
This test is intended for individuals with relevant clinical features or a suspected diagnosis of ornithine transcarbamylase deficiency. It is also designed for individuals with an abnormal newborn screen or biochemical results suggestive of OTC deficiency, which may include low citrulline and high glutamine levels, elevated urine orotic acid concentration, hyperammonemia, or unexpectedly low blood urea nitrogen (BUN). Additionally, reproductive partners of individuals with a known pathogenic variant in the OTC gene may benefit from this testing.
Special Instructions
Testing is available using either the exome or genome platform, and includes communication of results through myPrevent and consultation for test selection or result interpretation via the contact team.
Limitations
This test has not been cleared or approved by the US Food and Drug Administration. The performance characteristics have been validated by PreventionGenetics, following CAP and CLIA regulations.
Methodology
NGS
Biomarkers
Result Turnaround Time
14-16 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
